Cargando…

Non-glycosylated SARS-CoV-2 RBD elicited a robust neutralizing antibody response in mice

The glycosylated receptor-binding domain (glycoRBD) of SARS-CoV-2 can induce protective neutralizing antibodies to function as a vaccine. However, it is unclear whether vaccines using non-glycosylated RBD (non-glycoRBD) can induce protective immunity. Here, we report the efficacy of a SARS-CoV-2 non...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ke, Qian, Sun, Peng, Wang, Tiantian, Mi, Taotao, Xu, Huifang, Wu, Jun, Liu, Bo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier B.V. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075978/ https://www.ncbi.nlm.nih.gov/pubmed/35533747 http://dx.doi.org/10.1016/j.jim.2022.113279

Ejemplares similares

Kappa-RBD produced by glycoengineered Pichia pastoris elicited high neutralizing antibody titers against pseudoviruses of SARS-CoV-2 variants
por: Mi, Taotao, et al.
Publicado: (2022)

The SARS-CoV-2 mRNA-1273 vaccine elicits more RBD-focused neutralization, but with broader antibody binding within the RBD
por: Greaney, Allison J., et al.
Publicado: (2021)

Elicitation of potent neutralizing antibodies in obese mice by ISA 51-adjuvanted SARS-CoV-2 spike RBD-Fc vaccine
por: Li, Chia-Jung, et al.
Publicado: (2023)

A novel RBD-protein/peptide vaccine elicits broadly neutralizing antibodies and protects mice and macaques against SARS-CoV-2
por: Wang, Shixia, et al.
Publicado: (2022)

Antibodies Produced Toward Recombinant RBD and Nucleocapsid Neutralize SARS-COV-2
por: Rezaei, Amir, et al.
Publicado: (2022)

Glycan Masking of Epitopes in the NTD and RBD of the Spike Protein Elicits Broadly Neutralizing Antibodies Against SARS-CoV-2 Variants
por: Lin, Wei-Shuo, et al.
Publicado: (2021)

Distinct BCR repertoires elicited by SARS-CoV-2 RBD and S vaccinations in mice
por: Tian, Siyu, et al.
Publicado: (2021)

SARS-CoV-2 RBD dimers elicit response comparable to VLPs in mice
por: Love, J., et al.
Publicado: (2023)

Neutralizing monoclonal antibodies elicited by mosaic RBD nanoparticles bind conserved sarbecovirus epitopes
por: Fan, Chengcheng, et al.
Publicado: (2022)

An RBD bispecific antibody effectively neutralizes a SARS-CoV-2 Omicron variant
por: Yuan, Mengqi, et al.
Publicado: (2023)

Broad ultra-potent neutralization of SARS-CoV-2 variants by monoclonal antibodies specific to the tip of RBD
por: Ma, Hang, et al.
Publicado: (2022)

A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection
por: Shi, Juan, et al.
Publicado: (2022)

A pan-sarbecovirus vaccine based on RBD of SARS-CoV-2 original strain elicits potent neutralizing antibodies against XBB in non-human primates
por: Liu, Zezhong, et al.
Publicado: (2023)

Structural mechanism of SARS-CoV-2 neutralization by two murine antibodies targeting the RBD
por: Errico, John M., et al.
Publicado: (2021)

Design of the SARS-CoV-2 RBD vaccine antigen improves neutralizing antibody response
por: Dickey, Thayne H., et al.
Publicado: (2022)

Structure-based analyses of neutralization antibodies interacting with naturally occurring SARS-CoV-2 RBD variants
por: Xu, Hua, et al.
Publicado: (2021)

Recombinant SARS-CoV-2 RBD with a built in T helper epitope induces strong neutralization antibody response
por: Su, Qiu-Dong, et al.
Publicado: (2021)

Amantadine-assembled nanostimulator enhances dimeric RBD antigen-elicited cross-neutralization against SARS-CoV-2 strains
por: Zhang, Ye, et al.
Publicado: (2022)

Yeast-produced RBD-based recombinant protein vaccines elicit broadly neutralizing antibodies and durable protective immunity against SARS-CoV-2 infection
por: Zang, Jinkai, et al.
Publicado: (2021)

Potent RBD-specific neutralizing rabbit monoclonal antibodies recognize emerging SARS-CoV-2 variants elicited by DNA prime-protein boost vaccination
por: Chen, Yuxin, et al.
Publicado: (2021)

RBD and Spike DNA-Based Immunization in Rabbits Elicited IgG Avidity Maturation and High Neutralizing Antibody Responses against SARS-CoV-2
por: da Costa, Hernan H. M., et al.
Publicado: (2023)

An AAV vaccine targeting the RBD of the SARS-CoV-2 S protein induces effective neutralizing antibody titers in mice and canines
por: Liu, Fei, et al.
Publicado: (2022)

RBD(206)-sc-dimer induced robust cross-neutralization against SARS-CoV-2 and variants of concern
por: Zhou, Chuge, et al.
Publicado: (2021)

Tag-Free SARS-CoV-2 Receptor Binding Domain (RBD), but Not C-Terminal Tagged SARS-CoV-2 RBD, Induces a Rapid and Potent Neutralizing Antibody Response
por: Lin, Ting-Wei, et al.
Publicado: (2022)

The self-assembled nanoparticle-based trimeric RBD mRNA vaccine elicits robust and durable protective immunity against SARS-CoV-2 in mice
por: Sun, Wenqiang, et al.
Publicado: (2021)

Potent neutralizing RBD‐specific antibody cocktail against SARS‐CoV‐2 and its mutant
por: Jia, Lina, et al.
Publicado: (2021)

Serological reactivity of inactivated SARS-CoV-2 vaccine based on an S-RBD neutralizing antibody assay
por: Zhang, Hui, et al.
Publicado: (2022)

Direct capture of neutralized RBD enables rapid point-of-care assessment of SARS-CoV-2 neutralizing antibody titer
por: Connelly, Guinevere G., et al.
Publicado: (2022)

An ELISA Platform for the Quantitative Analysis of SARS-CoV-2 RBD-neutralizing Antibodies As an Alternative to Monitoring of the Virus-Neutralizing Activity
por: Kostin, N. N., et al.
Publicado: (2022)

A non-RBM targeted RBD specific antibody neutralizes SARS-CoV-2 inducing S1 shedding
por: Long, Yingyi, et al.
Publicado: (2021)

Intraduodenal Delivery of Exosome-Loaded SARS-CoV-2 RBD mRNA Induces a Neutralizing Antibody Response in Mice
por: Zhang, Quan, et al.
Publicado: (2023)

The molecular basis of the neutralization breadth of the RBD-specific antibody CoV11
por: Tolbert, William D., et al.
Publicado: (2023)

Glycosylated Delta-receptor-binding domain mucosal vaccine elicits broadly neutralizing antibodies with protection against SARS-CoV-2 challenge
por: Guan, Xiaoqing, et al.
Publicado: (2023)

Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2
por: Tai, Wanbo, et al.
Publicado: (2020)

Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern
por: Deshpande, Ashlesha, et al.
Publicado: (2021)

Characterization of SARS-CoV-2 Escape Mutants to a Pair of Neutralizing Antibodies Targeting the RBD and the NTD
por: Peter, Antonia Sophia, et al.
Publicado: (2022)

Human antibody recognition and neutralization mode on the NTD and RBD domains of SARS-CoV-2 spike protein
por: Otsubo, Ryota, et al.
Publicado: (2022)

A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern
por: Yuan, Mengqi, et al.
Publicado: (2022)

RBD decorated PLA nanoparticle admixture with aluminum hydroxide elicit robust and long lasting immune response against SARS-CoV-2
por: Meena, Jairam, et al.
Publicado: (2022)

Molecular basis for antiviral activity of two pediatric neutralizing antibodies targeting SARS-CoV-2 Spike RBD
por: Chen, Yaozong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2hrk3s1715jn509hj5r4c9k264